Professor Heerspink’s principal research interests include optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease in patients with diabetes with a specific focus on personalized medicine. He is Professor of Clinical Trials and Personalized Medicine; Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands; and visiting professor at the University of New South Wales in Sydney. He worked as a Postdoctoral Fellow at The George Institute for Global Health, Sydney, Australia, where he investigated the effects of blood pressure-lowering regimens on renal and cardiovascular outcomes in patients with chronic kidney disease.
Professor Heerspink leads and participates in clinical trials focused on renal and cardiovascular complications of Type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials. Based on his work at The George Institute, he was awarded a young investigator grant and subsequently in 2015 a consolidator investigator grant from the Dutch organization of scientific research and received in 2016 the Galien award for his research.
